Categories
Change Password!
Reset Password!
This study investigated the efficacy and safety of Tegoprazan-based therapies against Rabeprazole-based therapies for Helicobacter pylori (H. pylori) management in real-world clinical settings.
Both Tegoprazan and Rabeprazole-based therapies are equally effective and safe in eradicating H. pylori.
This study investigated the efficacy and safety of Tegoprazan-based therapies against Rabeprazole-based therapies for Helicobacter pylori (H. pylori) management in real-world clinical settings.
The study conducted a retrospective analysis of 1,474 patients with H. pylori infection, comparing outcomes of those treated with Tegoprazan (620 patients) and Rabeprazole (854 patients). The key outcome measure was H. pylori eradication rate, while the secondary outcome measure focused on adverse events.
In the intention-to-treat (ITT) and per-protocol (PP) analysis, the eradication rates for Tegoprazan and Rabeprazole were quite similar. The cumulative rate of adverse events was comparable across groups. However abdominal discomfort was markedly lower in the Tegoprazan group, as shown in Table 1 below.
Tegoprazan (potassium-competitive acid blocker) and Rabeprazole (proton-pump inhibitor) were similarly effective for H. pylori elimination with comparable safety profiles. Tegoprazan's effect on dose adjustments or use with bismuth-containing quadruple therapy needs further investigation, as its efficiency may be diminished in areas having high Clarithromycin resistance.
Journal of Gastroenterology and Hepatology
Efficacy and safety of Tegoprazan- and Rabeprazole-based concomitant therapies for Helicobacter pylori infection: Real-world evidence
Byung Wook Jung et. al.
Comments (0)